CanSino Biologics

CanSino Biologics (Chinese: 康希诺生物; pinyin: Kāngxīnuò Shēngwù), often abbreviated as CanSinoBIO, is a Chinese vaccine company.[1]

CanSino Biologics Inc.
CanSinoBIO
Native name
康希诺生物
Traded as
Founded2009 (2009) in Tianjin, China
Founders
  • Yu Xuefeng
  • Zhu Tao
  • Qiu Dongxu
  • Helen Mao Huihua
Headquarters
Tianjin
,
China
Website

History

CanSino Biologics was founded in 2009 in Tianjin, China by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua.[1]

In July 2018, it filed an application to list on the Hong Kong Stock Exchange.[1] It debuted on 28 March 2019 with an increase of 59%, the highest first day trading gain in Hong Kong since 2017.[2] In August 2020, it completed a secondary offering on Shanghai Stock Exchange's STAR market where it raised 5.2 billion yuan (US$750 million) by issuing 24.8 million shares.[3]

Vaccines
See also: COVID-19 vaccine

The company has a portfolio of vaccines under research including Ad5-EBOV to prevent Ebola and Ad5-nCoV for COVID-19. Both are developed jointly with the Institute of Biotechnology of the Academy of Military Medical Sciences of the People's Liberation Army.[1][4] The company has also collaborated with the National Research Council of Canada (NRC) on vaccine development. The two organizations began collaborating in 2013, and they later worked together to develop an Ebola vaccine.[5]

In March 2020, CanSino made a deal to collaborate with the NRC on development of the COVID-19 vaccine candidate Ad5-nCoV, to help end the COVID-19 pandemic, with plans to conduct a clinical trial in Canada.[6] Ad5-nCoV was the first COVID-19 vaccine candidate in the world to begin Phase II human trials.[5] The Phase II trial results were published in the peer-reviewed journal Lancet on July 20th, 2020 and noted neutralizing antibody and T cell responses in the 508 eligible participants.[7]

In early August, Saudi Arabia confirmed it would soon begin Phase III trials on 5,000 people for the vaccine developed by CanSino Biologics. Saudi Arabia plans to test the vaccine alongside a placebo on 5,000 volunteers and is currently preparing trials in the cities of Riyadh, Dammam, and Mecca. [8] Also in August, Mexico Foreign Minister Marcelo Ebrard announced Mexico aims to conduct Phase III trials for CanSino's vaccine and other vaccines in development by Johnson & Johnson and Walvax Biotechnology. Ebrard said trials would start between September and January, depending on approval from Mexico's food and drug agency. [9]

Investors

As of 2018, CanSino Biologics investors included Lilly Asia Ventures, Qiming Venture Partners and SDIC Fund Management.[1]

See also

References
  1. Ng, Eric (25 July 2018). "Chinese vaccine maker CanSino faces tough IPO sell in wake of Changsheng Bio-technology scandal". South China Morning Post. Retrieved 18 April 2020.
  2. Low, Zoe (29 March 2019). "Ebola vaccine maker CanSino Biologics has a plan to take its life-saving treatments well beyond China's domestic market". South China Morning Post. Retrieved 18 April 2020.
  3. Ren, Daniel (13 August 2020). "Covid-19 vaccine maker CanSino soars in Star Market debut". South China Morning Post. Retrieved 15 August 2020.
  4. Pinghui, Zhuang (10 April 2020). "Volunteers needed for second phase of China coronavirus vaccine trial". South China Morning Post. Beijing. Retrieved 18 April 2020.
  5. Canada, National Research Council. "The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19". www.newswire.ca. Retrieved 19 May 2020.
  6. DeArment, Alaric (13 May 2020). "CanSino Biologics may start clinical development of Covid-19 vaccine in Canada". MedCity News. Retrieved 19 May 2020.
  7. Zhu, Feng-Cai; Guan, Xu-Hua; Li, Yu-Hua; Huang, Jian-Ying; Jiang, Tao; Hou, Li-Hua; Li, Jing-Xin; Yang, Bei-Fang; Wang, Ling; Wang, Wen-Juan; Wu, Shi-Po; Wang, Zhao; Wu, Xiao-Hong; Xu, Jun-Jie; Zhang, Zhe; Jia, Si-Yue; Wang, Bu-Sen; Hu, Yi; Liu, Jing-Jing; Zhang, Jun; Qian, Xiao-Ai; Li, Qiong; Pan, Hong-Xing; Jiang, Hu-Dachuan; Deng, Peng; Gou, Jin-Bo; Wang, Xue-Wen; Wang, Xing-Huan; Chen, Wei (August 2020). "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial". The Lancet. 396 (10249): 479–488. doi:10.1016/S0140-6736(20)31605-6.
  8. Eltahir, Nafisa (9 August 2020). "CanSino to start Phase III trial of COVID-19 vaccine in Saudi". Reuters. Retrieved 9 August 2020.
  9. Daniel, Frank Jack (12 August 2020). "Mexico to trial China, U.S. COVID-19 vaccines, may produce some". Reuters. Retrieved 15 August 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.